Health & Wellness

Atlantic Health System Cancer Care First to Begin Clinical Trial for Late-Stage Melanoma of Novel Virus-Based Immunotherapy

42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg
Credits: COURTESY PHOTO
42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg

MORRISTOWN, NJ  – Atlantic Health System Cancer Care is the first oncology institution in the world to sign on to, and to enroll the first patient in, a multicenter Phase IIa clinical trial of OBP-301 (Telomelysin), a virus-based immunotherapy for late-stage melanoma that has not responded to other treatments. 

This leading-edge experimental therapy, which is under development by Japanese biotechnology company Oncolys BioPharma, uses the common cold virus to modify a gene that can selectively replicate in, and destroy, cancer cells. The study protocol was approved by the U.S. Food and Drug Administration (FDA) in June.

The clinical trial is being led locally by Eric D. Whitman, MD, FACS, medical director of Atlantic Health System Cancer Care and director of the Carol G. Simon Cancer Center’s Atlantic Melanoma Center at Morristown Medical Center and Overlook Medical Center.

Sign Up for E-News

“This targeted immunotherapy holds great promise for improving survival rates in patients with unresectable and metastatic melanoma,” said Whitman. “We are proud to have been chosen as the first site for this leading edge clinical trial, and happy to be able to offer a wide range of the latest established and experimental treatments to our patients.”

Melanoma, the most serious form of skin cancer, affects more than 50,000 people each year. Although the chances of having melanoma increase with age, the number of cases among young adults is rising every year. Melanoma can have serious health consequences and may even be fatal.

The OBP-301 trial is a multicenter, Phase IIa study to evaluate how melanoma tumors respond to injection of this drug in patients with Stage III and Stage IV melanoma - that is, to determine how much the drug shrinks or destroys tumors after it is injected into them. The study, which will also look at potential side effects, is “open label,” meaning that all participants in the study will receive OBP-301. 

OBP-301 is a type of virus known as an adenovirus. Adenoviruses are common in nature and when they multiply in normal human cells they may cause infections that result in symptoms like those of the common cold or the flu.  OBP-301 has been genetically changed from the original virus to reproduce in target cancer cells that are emitting a certain signal. As a result of this reproduction, OBP-301 is believed to burst and kill tumor cells.

Study participants will receive multiple injections into their tumors over a period of several weeks.  Blood tests will be done to evaluate the level of virus in patients’ systems, and for immune response monitoring. Whitman and colleagues will also evaluate how long it takes to get a response and how long responses last, as well as overall survival and progression-free survival rates.

In preclinical studies, Oncolys demonstrated OBP-301’s anti-tumor activity in various types of cancer cells. A Phase I clinical trial in the U.S. demonstrated the drug’s safety, and showed that it shrank tumors in a majority of study participants, who had a variety of solid tumors. Additional studies of the drug have been completed, or are underway, in Japan, Korea and Taiwan.

The Atlantic Melanoma Center, a clinical and research center of excellence, is an internationally-recognized program. The center’s multidisciplinary approach -- combining the expertise of board-certified surgeons, medical oncologists, pathologists, radiation oncologists and nurses – treats all forms of melanoma, including those in the skin, mucous membranes and eyes. Patients receive the latest medical treatments, and when needed, melanoma surgery is also available. 

For more information on the OBP-301 clinical trial or other studies, call the Atlantic Melanoma Center at 973-971-7111.  

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Flemington/Raritan

Voter Turnout in Raritan Township

June 15, 2018

To the editor,

We want to share our admiration for all of the Raritan Township residents who came out to vote in the June 5 Primary Election. Additionally, we want to say "thank you" to our Democratic supporters for their votes.

As we look to the General Election on Nov. 6, we reflect on the importance of this election for our children, seniors and all those in between as we ...

Alzheimer's is Public Health Crisis

To the editor:

 

With more than 5 million Americans now living with Alzheimer’s and with more than 15 million acting as caregivers, Alzheimer’s has become the nation’s most expensive disease. This year alone, it will cost $277 billion to take care of those stricken. The Alzheimer’s Association predicts that, by 2050, more than 14 million Americans will be ...

Candidates 'Weaponized' News Article

To the editor:

I was dismayed to see my 2014 news reportage inaccurately weaponized by council members Marc Hain and Brooke Warden in their campaign flier attacking Al Brewer. The headline “School security at issue: Flemington-Raritan board member accused of leaking secrets” is less than a half-truth, given the ensuing revelation.

Marc and Brook ignored my follow-up report in ...

Upcoming Events

Carousel_image_74a8914ea73d125c58fc_a1ebc45f9ab90ef3e8c6_c0caf2d5e2dceef79bda_20180220_124359

Tue, June 19, 12:00 PM

Al Fresco's, Flemington

Small-biz-Networking Meetup

Business & Finance

Mon, June 25, 9:00 AM

Flemington Public Library, Flemington

Coding Camp at Mediatech

Education

AtlantiCast

AtlantiCast: Episode 16

Summer is in the air, and the latest episode of AtlantiCast is ready to help you enjoy some fun outdoors while staying safe! This week’s episode opens with tips for sunscreen usage from Atlantic Health System’s Chief Medical and Academic Officer, Dr. Jan Schwarz-Miller. You’ll also learn about how Atlantic Health System is advancing the future of health care through ...

Voter Turnout in Raritan Township

June 15, 2018

To the editor,

We want to share our admiration for all of the Raritan Township residents who came out to vote in the June 5 Primary Election. Additionally, we want to say "thank you" to our Democratic supporters for their votes.

As we look to the General Election on Nov. 6, we reflect on the importance of this election for our children, seniors and all those in between as we ...